Lifestyle and Glucose Lowering Medication in T2DM
Diabetes Mellitus, Type 2

About this trial
This is an interventional treatment trial for Diabetes Mellitus, Type 2 focused on measuring lifestyle, exercise, physical activity, diet, glycemic control, hba1c, glucose lowering drugs
Eligibility Criteria
Inclusion Criteria:
- Less than three anti-diabetic medications.
- Diabetes 2 duration of max 10 years
- BMI >25 but <40 kg/m2,
- Accept of medical regulation by the UTURN endocrinologists only
- Accept of purchasing a fitness club membership through U-TURN collaborator
Exclusion Criteria:
- Hba1c> 9% (75 mmol/mol)
- Insulin usage
- Presence of one or more of the following micro- and macrovascular complications of T2DM; a.Diabetic retinopathy (except mild nonproliferative retinopathy or early proliferative retinopathy) b. Macro-albuminuria or nephropathy c. Diabetic neuropathy (except mild affected vibratory testing (<50 Volt)) d. Arterial insufficiency e. Ischemic heart disease
- Steroid treatment (inhalation) until three months before the medical examination
- TSH raised/below the normal range
- Liver disease (ALAT/ASAT thrice normal range)
- Inability or contraindication to increased levels of physical activity (Pedersen BK and Saltin B)
- Evidence of anaemia
- Lung disease (except mild asthma and mild chronic obstructive pulmonary disease)
- Heart disease
- Kidney disease (creatinine above 130 µM or macro albuminuria)
- Pregnancy
Sites / Locations
- Center for Physical Activity Research, Copenhagen University Hospital
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
U-TURN intervention
Standard care
The intervention group will receive an intensive lifestyle intervention including partly supervised aerobic and strength exercise, diet plans and counseling by clinical dietitians. All exercise will be supervised initially and the supervision will be reduced gradually across the 12-month intervention. Additionally, the participants will be offered educational classes on implementation of a healthy lifestyle and diabetes education and support by trained nurses. Participants in this group will have their pharmacological treatment regulated by the study endocrinologists using a standardized pharmacological treatment. The treatment is in accordance with the Danish guidelines.
The reference group will receive diabetes education and support by trained nurses. Participants in this group will have their pharmacological treatment regulated by the study endocrinologists using a standardized pharmacological treatment. The treatment is in accordance with the Danish guidelines.